Summary:
- The article discusses Ridymo, a biotechnology company, that has designed a cyclic peptide to target the undruggable β-catenin protein within a remarkably short timeframe of two months.
- β-catenin is a key component of the Wnt signaling pathway, which is implicated in various types of cancer, and has been considered a challenging target for drug development.
- Ridymo's achievement in rapidly designing a cyclic peptide that can potentially modulate the activity of β-catenin represents a significant advancement in the field of targeted cancer therapy.